Publications
|
|
Development of ADS051, an oral, gut-restricted, small molecule neutrophil modulator for the treatment of neutrophil-mediated inflammatory diseasesJuly 1, 2023 |
|---|
|
|
A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseasesJune 22, 2023 |
|---|
|
|
ADS051, AN ORAL, GUT-RESTRICTED, SMALL MOLECULE NEUTROPHIL MODULATOR IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING MULTIPLE ASCENDING DOSES |
|---|
|
|
ADS032, a novel dual NLRP1/3 inflammasome inhibitor for the treatment of lung inflammation |
|---|
|
|
Safety, tolerability and pharmacokinetics of BT051, an oral inhibitor of neutrophil migration and activation in clinical development for Inflammatory Bowel Disease |
|---|